A detailed history of Marshall Wace, LLP transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 353,562 shares of VINC stock, worth $109,604. This represents 0.0% of its overall portfolio holdings.

Number of Shares
353,562
Previous 328,533 7.62%
Holding current value
$109,604
Previous $266,000 4.51%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.51 - $0.84 $12,764 - $21,024
25,029 Added 7.62%
353,562 $254,000
Q2 2024

Aug 14, 2024

BUY
$0.57 - $6.6 $146,471 - $1.7 Million
256,967 Added 359.06%
328,533 $266,000
Q1 2024

May 15, 2024

BUY
$1.07 - $8.06 $76,575 - $576,821
71,566 New
71,566 $362,000
Q4 2021

Feb 14, 2022

SELL
$0.0 - $0.0 $0 - $0
-22,444 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$0.0 - $0.0 $0 - $0
-25,922 Reduced 53.6%
22,444 $363,000
Q2 2021

Aug 13, 2021

BUY
$0.0 - $27.0 $0 - $1.31 Million
48,366 New
48,366 $628,000

Others Institutions Holding VINC

About Vincerx Pharma, Inc.


  • Ticker VINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,189,800
  • Market Cap $6.57M
  • Description
  • Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...
More about VINC
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.